

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Long-term follow-up of the Phase III KEYNOTE-006 study of pembrolizumab versus ipilimumab for advanced melanoma reported which of the following clinical findings?**
 - No significant difference in overall survival (OS) outcomes at 7 years with pembrolizumab versus ipilimumab
 - Sustained and significant improvement in OS outcomes at 7 years with pembrolizumab versus ipilimumab**
 - Inferior OS outcomes at 7 years with pembrolizumab versus ipilimumab
- 2. What is the mechanism of OBX-115, an investigational agent being evaluated for immune checkpoint inhibitor-resistant unresectable or metastatic melanoma?**
 - Chimeric antigen receptor T-cell therapy
 - Bispecific antibody
 - Tumor-infiltrating lymphocyte cell therapy**
 - Antibody-drug conjugate
- 3. In a Phase II study of neoadjuvant and adjuvant pembrolizumab versus adjuvant pembrolizumab alone for Stage IIIB to Stage IVC melanoma, what efficacy outcome was reported?**
 - Inferior event-free survival (EFS) outcomes with neoadjuvant-adjuvant pembrolizumab versus adjuvant pembrolizumab alone
 - No significant difference in EFS between neoadjuvant-adjuvant pembrolizumab and adjuvant pembrolizumab alone
 - Significant improvement in EFS with neoadjuvant-adjuvant pembrolizumab over adjuvant pembrolizumab alone**
- 4. A 3-year update of the Phase II study evaluating the mRNA vaccine mRNA-4147/V940 combined with pembrolizumab versus pembrolizumab alone for resected high-risk melanoma has demonstrated which of the following outcomes?**
 - No significant improvement in recurrence-free survival (RFS) with the combination
 - A significant improvement in RFS with the combination**
 - Inferior RFS with the combination
- 5. Long-term follow-up of the Phase III COMBI-AD study of adjuvant dabrafenib in combination with trametinib versus placebo for Stage III BRAF-mutated melanoma reported which of the following efficacy outcomes?**
 - Inferior OS outcomes in the intention-to-treat population with dabrafenib in combination with trametinib
 - A numerical, but not statistically significant, improvement in OS with dabrafenib in combination with trametinib**
 - Superior and significant improvement in OS with dabrafenib in combination with trametinib